News & Updates
Filter by Specialty:
Seladelpar safe, effective for primary biliary cholangitis
In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.
Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022
Hepatitis B virus treatment rates still low among eligible patients
Administration rates of antiviral therapy remain low among treatment-eligible patients with chronic hepatitis B virus (CHB) and among CHB patients without human immunodeficiency virus (HIV), reveals a recent study.
Hepatitis B virus treatment rates still low among eligible patients
10 Apr 2022
CRP thresholds inform success of dexamethasone, tocilizumab against COVID-19 mortality
Using C-reactive protein (CRP) levels as indicators for early treatment with tocilizumab and dexamethasone can help reduce mortality in hospitalized patients with the coronavirus disease 2019 (COVID-19), a recent study has found.
CRP thresholds inform success of dexamethasone, tocilizumab against COVID-19 mortality
10 Apr 2022
Aspirin-statin combo lowers hepatocellular carcinoma incidence
Daily use of aspirin reduces the risk of incident hepatocellular carcinoma (HCC), while the combination of daily aspirin use and statin results in a lower incidence of HCC, which suggests a beneficial interaction, according to a study. In addition, no excess oesophageal variceal haemorrhage (VH) is seen among daily aspirin users compared with nonusers.
